Yam C, et al. - The results of the first prospective phase II trial evaluating the efficacy of the novel combination of tipifarnib and gemcitabine in the treatment of metastatic breast cancer were reported. Researchers observed that with high rates of myelosuppression, the combination of tipifarnib and gemcitabine was not well tolerated. Furthermore, it proved not superior to gemcitabine monotherapy in efficacy in the treatment of metastatic breast cancer.